Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q2 earnings results on Thursday, July 28, 2022 at 08:00 AM.
Here’s what investors need to know about the announcement.
Earnings
Alnylam Pharmaceuticals missed estimated earnings by 25.31%, reporting an EPS of $-2.03 versus an estimate of $-1.62.
Revenue was up $4.26 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.35 which was followed by a 6.8% drop in the share price the next day.
Here’s a look at Alnylam Pharmaceuticals’s past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -1.84 | -1.54 | -1.57 | -1.6 |
| EPS Actual | -1.49 | -1.69 | -1.51 | -1.3 |
| Revenue Estimate | 243.02M | 233.62M | 218.69M | 193.18M |
| Revenue Actual | 213.26M | 258.54M | 187.63M | 220.55M |
To track all earnings releases for Alnylam Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
